Your browser is no longer supported. Please, upgrade your browser.
Settings
CNCE Concert Pharmaceuticals, Inc. daily Stock Chart
CNCE [NASD]
Concert Pharmaceuticals, Inc.
Index- P/E3.45 EPS (ttm)4.41 Insider Own3.10% Shs Outstand22.68M Perf Week9.25%
Market Cap345.42M Forward P/E- EPS next Y-2.58 Insider Trans-5.64% Shs Float20.88M Perf Month10.76%
Income103.50M PEG- EPS next Q-0.63 Inst Own75.90% Short Float3.62% Perf Quarter-6.74%
Sales154.30M P/S2.24 EPS this Y278.00% Inst Trans0.05% Short Ratio5.83 Perf Half Y-20.51%
Book/sh8.56 P/B1.78 EPS next Y-24.60% ROA47.50% Target Price26.17 Perf Year9.10%
Cash/sh8.39 P/C1.82 EPS next 5Y- ROE51.50% 52W Range12.33 - 30.71 Perf YTD-41.13%
Dividend- P/FCF3.35 EPS past 5Y33.20% ROI46.60% 52W High-50.40% Beta1.00
Dividend %- Quick Ratio33.90 Sales past 5Y62.10% Gross Margin- 52W Low23.52% ATR0.75
Employees64 Current Ratio33.90 Sales Q/Q-86.70% Oper. Margin- RSI (14)54.86 Volatility4.97% 5.45%
OptionableYes Debt/Eq0.00 EPS Q/Q50.60% Profit Margin67.00% Rel Volume1.09 Prev Close15.30
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout0.00% Avg Volume129.57K Price15.23
Recom2.00 SMA204.88% SMA502.06% SMA200-18.88% Volume140,771 Change-0.46%
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Oct-12-18 09:15AM  Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-10-18 01:56PM  What is Behind Concert Pharmaceuticals Incs (NASDAQ:CNCE) Superior ROE? Simply Wall St.
Sep-26-18 07:00AM  Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata Business Wire +5.14%
Aug-29-18 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-09-18 06:35AM  Inside Concert Pharma's new HQ in popular Lexington biotech campus American City Business Journals
Aug-07-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of Marin, Eclipse Resources, MKS Instruments, and Container Store Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-05-18 11:18PM  Edited Transcript of CNCE earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:10AM  Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates Zacks +8.75%
10:06AM  Concert: 2Q Earnings Snapshot Associated Press
07:00AM  Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update Business Wire
Jul-26-18 07:00AM  Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018 Business Wire
May-09-18 01:46PM  Edited Transcript of CNCE earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-03-18 08:27AM  Concert: 1Q Earnings Snapshot Associated Press +7.13%
07:00AM  Concert Pharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
Apr-27-18 07:30AM  Wired News Concert Pharma Enrolled Last Patient in Phase-2a Trial Evaluating CTP-543 in Alopecia Areata ACCESSWIRE
Apr-26-18 07:00AM  Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences Business Wire
Apr-25-18 07:00AM  Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata Business Wire
Apr-23-18 07:35AM  Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop, Columbia Banking System, and New Jersey Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-06-18 04:11PM  Edited Transcript of CNCE earnings conference call or presentation 1-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
07:00AM  Concert Pharmaceuticals Present at Upcoming Investor Conferences Business Wire
Mar-01-18 08:13AM  Concert reports 4Q loss Associated Press
07:00AM  Concert Pharmaceuticals Reports Year Ended 2017 Financial Results Business Wire
06:30AM  Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 04:05PM  Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia Business Wire
Feb-22-18 08:10AM  Report: Developing Opportunities within M.D.C., Concert Pharmaceuticals, WellCare Health Plans, Dextera Surgical, Continental Resources, and Western Union Future Expectations, Projections Moving into 2018 GlobeNewswire
Feb-21-18 07:00AM  Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018 Business Wire
Feb-12-18 07:00AM  Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata Business Wire
Jan-17-18 06:55AM  Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News Zacks
Jan-16-18 05:50AM  Concert Pharma shares hit low note on patent challenge denial American City Business Journals
Jan-15-18 03:10PM  Concert Pharmaceuticals Plunges on Patent Petition Setback Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences Corporation ACCESSWIRE
Jan-12-18 03:18PM  Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today Motley Fool -27.20%
01:48PM  Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades Benzinga
07:05AM  FDA Grants Fast Track Designation to Concert Pharmaceuticals CTP-543 for the Treatment of Alopecia Areata Business Wire
07:00AM  Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding Business Wire
Dec-26-17 11:23AM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-18-17 07:00AM  Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer Business Wire
Dec-13-17 07:00AM  Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index Business Wire
Dec-11-17 01:42PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017 Capital Cube
Dec-04-17 08:52AM  Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session Zacks
Dec-01-17 10:33AM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017 Capital Cube +5.72%
Nov-30-17 09:43AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 Capital Cube
Nov-13-17 05:42PM  Edited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMT Thomson Reuters StreetEvents +5.93%
Nov-09-17 10:50AM  Concert posts 3Q profit Associated Press
08:23AM  Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update Business Wire
Nov-06-17 08:52AM  Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)? Simply Wall St.
07:00AM  Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial Business Wire
Nov-02-17 07:00AM  Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences Business Wire
Oct-19-17 04:30PM  Why General Electric, Concert Pharmaceuticals, and NVR Jumped Today Motley Fool +18.19%
01:00PM  Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent Business Wire
Oct-17-17 10:10AM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : October 17, 2017 Capital Cube
Oct-16-17 08:33AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017 Capital Cube
Sep-21-17 10:18AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : September 21, 2017 Capital Cube
Aug-31-17 07:00AM  Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference Business Wire
Aug-24-17 10:18AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 05:26PM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : August 23, 2017 Capital Cube
Aug-22-17 10:20AM  Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media Zacks
09:01AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017 Capital Cube
Aug-13-17 05:24PM  Edited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 10:08AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 11, 2017 Capital Cube
Aug-08-17 11:55PM  Concert reports 2Q loss Associated Press
07:00AM  Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
05:40AM  Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 07:00AM  Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017 Business Wire
Jul-25-17 04:01PM  Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656 Business Wire
Jul-24-17 07:00AM  Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex Business Wire +14.75%
Jul-18-17 08:48AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : July 18, 2017 Capital Cube
Jul-10-17 08:20AM  FDA lifts hold on Concert Pharma's study testing hair loss drug Reuters
07:40AM  FDA lifts hold on Concert Pharma's hair loss drug Reuters
07:30AM  FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 Business Wire
Jul-07-17 09:37AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : July 7, 2017 Capital Cube
Jun-26-17 05:45PM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : June 26, 2017 Capital Cube
Jun-23-17 08:13AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : June 23, 2017 Capital Cube
Jun-12-17 07:00AM  Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital Business Wire
May-30-17 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire -8.88%
07:00AM  Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws Business Wire
May-24-17 10:00AM  Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals Business Wire
May-22-17 06:29PM  Vertex Undergoes FTC Scrubbing for Deal on CF Treatment TheStreet.com
07:00AM  Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act Business Wire
May-18-17 10:21AM  Concert Pharma Falls After Clinical Hold on Hair Loss Drug Zacks
May-17-17 12:39PM  FDA places clinical hold on Concert Pharma's hair loss drug Reuters -7.48%
09:52AM  Hold on Concert's Hair Loss Trials Pushes Shares Down 10% TheStreet.com
09:33AM  Concert Pharma stock drops 10% after FDA puts hair loss drug on clinical hold MarketWatch
07:30AM  Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial Business Wire
May-04-17 03:49PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : May 4, 2017 Capital Cube
08:50AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : May 4, 2017 Capital Cube
May-03-17 11:14AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 Capital Cube
May-02-17 12:55PM  Edited Transcript of CNCE earnings conference call or presentation 2-May-17 12:30pm GMT Thomson Reuters StreetEvents
07:23AM  Concert reports 1Q loss Associated Press
07:15AM  Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:00AM  Concert Pharmaceuticals Reports First Quarter 2017 Financial Results Business Wire
06:30AM  Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata Business Wire
Apr-25-17 07:00AM  Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences Business Wire
Apr-07-17 04:12PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Mar-26-17 02:00PM  Why Concert Pharmaceuticals Is Music to Investors' Ears TheStreet.com
02:00PM  Why Concert Pharmaceuticals Is Music to Investors' Ears
Mar-24-17 10:50AM  Concert rebuffed $250M buyout offer from Vertex before CF drug deal at bizjournals.com
10:50AM  Concert rebuffed $250M buyout offer from Vertex before CF drug deal American City Business Journals
05:32AM  Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher? Zacks
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stuart NancyChief Operating OfficerJul 10Sale17.9426,127468,69789,958Jul 11 04:04 PM
Stuart NancyChief Operating OfficerJul 09Sale17.565,29192,890116,085Jul 11 04:04 PM
Cassella James VChief Development OfficerApr 17Sale20.1810,582213,51030,000Apr 19 04:07 PM
Tung Roger DChief Executive OfficerMar 02Option Exercise4.5827,757127,127650,855Mar 05 04:29 PM
ALDRICH RICHARDDirectorFeb 01Sale19.991,94638,9010Feb 01 04:36 PM
ALDRICH RICHARDDirectorJan 31Sale20.815,000104,0531,946Feb 01 04:36 PM
ALDRICH RICHARDDirectorJan 30Sale21.335,000106,6506,946Feb 01 04:36 PM
ALDRICH RICHARDDirectorJan 29Sale21.365,000106,80011,946Jan 29 05:43 PM
ALDRICH RICHARDDirectorJan 26Sale20.465,000102,30016,946Jan 29 05:43 PM
Stuart NancyChief Operating OfficerJan 25Option Exercise4.5848,882223,880151,860Jan 26 04:21 PM
ALDRICH RICHARDDirectorJan 25Sale20.288,054163,30221,946Jan 29 05:43 PM
ALDRICH RICHARDDirectorJan 24Sale19.8310,000198,30026,946Jan 24 04:43 PM
ALDRICH RICHARDDirectorJan 23Sale19.6810,000196,75031,946Jan 24 04:43 PM
ALDRICH RICHARDDirectorJan 22Sale19.5510,000195,45036,946Jan 24 04:43 PM
ALDRICH RICHARDDirectorJan 19Sale19.6610,000196,55041,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 18Sale19.4010,000193,95046,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 17Sale18.9910,000189,90051,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 16Option Exercise3.6521,23677,405308,211Jan 18 04:26 PM
ALDRICH RICHARDDirectorJan 16Sale19.2710,000192,65056,946Jan 18 04:26 PM
ALDRICH RICHARDDirectorJan 16Sale19.0821,236405,183286,975Jan 18 04:26 PM
BVF PARTNERS L P/IL10% OwnerDec 19Sale26.651,282,85634,188,112122,496Dec 21 07:40 PM
Barrett Ronald WDirectorDec 04Option Exercise3.6514,15651,59914,156Dec 06 04:48 PM
Barrett Ronald WDirectorDec 04Sale24.7014,156349,6530Dec 06 04:48 PM
Tung Roger DChief Executive OfficerNov 17Option Exercise4.587,34033,617626,305Nov 20 04:12 PM
Stuart NancyChief Operating OfficerNov 14Option Exercise4.584,21519,305105,117Nov 15 04:09 PM
BVF PARTNERS L P/IL10% OwnerOct 19Buy15.84331,9165,256,7201,619,249Oct 23 05:43 PM